FrancophonIA/ELRC3.0 huggingface dataset:
English: These include: Dianeal, Extraneal and Nutrineal solutions for peritoneal dialysis; Monosol and a sodium chloride solution for haemodialysis.
Estonian: Need on peritoneaaldialüüsiks kasutatavad Dianeal, Extraneal ja Nutrineal ning hemodialüüsiks kasutatavad Monosol ja naatriumkloriidilahus.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has finalised recommendations to ensure the adequate supply of these dialysis solutions in the EU while measures are being put in place at Castlebar to enable the production of endotoxin-free solutions.
Estonian: Ravimiameti inimravimite komitee on koostanud soovitused, mille eesmärk on tagada dialüüsilahuste piisav kättesaadavus ELis ajavahemikul, kui Castlebaris võetakse meetmeid endotoksiinivabade lahuste tootmise tagamiseks.
English: What is the background to the current investigation?
Estonian: Uurimise taust
English: The Agency was made aware of the presence of endotoxins in batches of Dianeal, Extraneal and Nutrineal made in the Castlebar plant in December 2010.
Estonian: Ravimiametile teatati detsembris 2010, et Castlebaris asuvas tootmisettevõttes valmistatud Dianeali, Extraneali ja Nutrineali partiides leidub endotoksiine.
English: At the time, the company identified endotoxin-producing bacteria in two tanks as the root cause of the problem and removed the tanks from the production line.
Estonian: Ettevõte tuvastas siis probleemi algpõhjusena endotoksiine tootvad bakterid kahes mahutis, mis eemaldati tootmisliinilt.
English: The investigation follows the detection in December 2010 of endotoxins in dialysis solutions produced at the plant.
Estonian: Uurimine algatati pärast tootmisettevõttes toodetud dialüüsilahustes endotoksiinide tuvastamist detsembris 2010.
English: Dialysis solutions are used in patients with kidney problems to help clear waste substances (such as urea) from the blood.
Estonian: Dialüüsilahuseid kasutatakse neeruprobleemidega patsientide verest jääkainete (nt karbamiidi) eemaldamiseks.
English: Aseptic peritonitis can force the patient to stop dialysis until it is resolved.
Estonian: Patsient võib olla sunnitud dialüüsi katkestama, kuni aseptiline peritoniit on taandunud.
English: The CHMP noted that improvements are being made to Castlebar plant to ensure future production of endotoxin-free dialysis solutions.
Estonian: Inimravimite komitee märkis, et Castlebari tootmisettevõttes tehakse ümberkorraldusi endotoksiinivabade dialüüsilahuste tootmiseks.
English: The products affected by this review are some of the dialysis solutions produced at Baxter's Castlebar plant.
Estonian: Läbivaatamise käigus uuriti mõningaid Baxteri Castlebari tootmisettevõttes toodetud dialüüsilahuseid.
English: The tablets should be taken at the same time each day.
Estonian: Tabletid tuleb võtta iga päev samal kellaajal.
English: Daxas received a marketing authorisation valid throughout the EU on 5 July 2010.
Estonian: Daxas on saanud müügiloa, mis kehtib kogu ELis, 5. juulil 2010.
English: What measures are being taken to ensure the safe and effective use of Daxas?
Estonian: Mis meetmed võetakse, et tagada Daxase ohutu ja efektiivne kasutamine?
English: The company is also carrying out an observational study on the long-term safety of the medicine.
Estonian: Peale selle korraldab ettevõte ravimi pikaajalise ohutuse vaatlusuuringu.
English: Further information on Daxas can be found on the Agency's website: ema.europa/Find medicine/Human medicine/European public assessment reports.
Estonian: Lisateave Daxase kohta on ameti veebilehel: ema.europa/Find medicine/Human medicine/European public assessment reports.
English: After considering all of the available data on the effects of the medicine, the Agency decided that Daxas's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Olles kaalunud kõiki kättesaadavaid andmeid ravimi toime kohta, otsustas amet, et Daxase kasulikkus on suurem kui sellega kaasnevad riskid, ja lubati ravimi kasutamine ELis.
English: At the beginning of the studies, both groups of patients had an FEV1 of around 1 litre (1,000 ml).
Estonian: Uuringute alguses oli mõlema rühma patsientide FEV1 ligikaudu 1 liiter (1000 ml).
English: The company will also provide cards for patients, telling them what information about their symptoms and past illnesses they need to give their doctor to help the doctor determine whether Daxas is appropriate for them.
Estonian: Samuti annab ettevõte patsientidele teabekaardid, kus on selgitatud, millistest sümptomitest ja varasematest haigustest peavad patsiendid arstile teatama, et arst oskaks otsustada, kas Daxas sobib neile.
English: The doctor may stop treatment with Daxas if the patient loses too much weight.
Estonian: Arst võib lõpetada Daxasega toimuva ravi, kui patsiendi kaalulangus on liiga suur.
English: Because patients taking Daxas may lose weight, they are advised to weigh themselves on a regular basis.
Estonian: Et Daxast võtvate patsientide kehakaal võib väheneda, soovitatakse neil end regulaarselt kaaluda.
English: As for all medicines, data on the use of Daxas are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Daxase kasutamise kohta pidevat järelevalvet.
English: Daxas contains the active substance roflumilast.
Estonian: Daxas sisaldab toimeainena roflumilasti.
English: What is Daxas and what is it used for?
Estonian: Mis on Daxas ja milleks seda kasutatakse?
English: The patients could continue to receive treatment with a bronchodilator during the study.
Estonian: Uuringute ajal võisid patsiendid jätkata ravi bronhodilataatoriga.
English: Other information about Daxas:
Estonian: Muu teave Daxase kohta
English: Side effects reported with Daxas are carefully evaluated and any necessary action taken to protect patients.
Estonian: Daxase kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Daxas have also been included in the summary of product characteristics and the package leaflet.
Estonian: Daxase ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Patients started on the lower dose had fewer side effects.
Estonian: Patsientidel, kes alustasid ravi väiksema annusega, oli vähem kõrvalnähte.
English: For more information about using Daxas, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Daxase kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The company that makes Daxas will ensure that healthcare professionals who will prescribe the medicine in all Member States of the European Union (EU) are provided with educational materials containing information on the medicine's side effects and how it should be used.
Estonian: Daxase tootja tagab, et ravimit välja kirjutavad tervishoiutöötajad kõikides Euroopa Liidu liikmesriikides saavad ravimi kõrvalnähte ja kasutamist käsitlevad teabematerjalid.
English: The active substance in Daxas, roflumilast, belongs to a group of medicines called ‘phosphodiesterase type 4 (PDE4) inhibitors'.
Estonian: Daxase toimeaine roflumilast kuulub fosfodiesteraas-4 (PDE4) inhibiitorite ravimirühma.
English: Daxas must not be used in patients who have moderate or severe problems with their liver.
Estonian: Seda ei tohi kasutada mõõdukate või raskete maksaprobleemidega patsiendid.
English: The most common side effects with Daxas (seen in between 1 and 10 patients in 100) are decreased weight, decreased appetite, insomnia (difficulty sleeping), headache, diarrhoea, nausea (feeling sick) and abdominal pain (stomach ache).
Estonian: Daxase kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on kehakaalu vähenemine, isutus, unetus, peavalu, kõhulahtisus, iiveldus ja kõhuvalu.
English: The European Medicines Agency noted that there was a need for new COPD treatments and that the main studies showed a modest benefit of Daxas 500 micrograms in patients with severe COPD.
Estonian: Euroopa Ravimiamet märkis, et vajadus uute kroonilise obstruktiivse kopsuhaiguse ravimite järele on olemas ja et põhiuuringutes tõendati Daxase 500-mikrogrammise annuse mõõdukat kasulikkust raske kopsuhaigusega patsientide ravis.
English: For the full list of side effects of Daxas, see the package leaflet.
Estonian: Daxase kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Around 18% (81 of 441 patients) of those started at 250 micrograms daily dropped out of the study, compared with 25% (109 of 443) of those starting with 500 micrograms daily.
Estonian: Uuringu katkestas ligikaudu 18% (81 patsienti 441st) nendest patsientidest, kes alustasid ravi 250 mikrogrammiga ööpäevas, ning 25% (109 patsienti 443st) nendest patsientidest, kes alustasid ravi 500 mikrogrammiga ööpäevas.
English: The recommended dose of Daxas for treatment is one 500-microgram tablet once a day, but treatment is started with one 250-microgram tablet daily to reduce side effects that might make patients stop taking the medicine.
Estonian: Daxase soovitatav raviannus on üks 500-mikrogrammine tablett üks kord ööpäevas, kuid ravi alustatakse ühe 250-mikrogrammise tabletiga ööpäevas, et vähendada kõrvalnähte, mille tõttu patsiendid võivad ravi katkestada.
English: Although a dose of 250 micrograms daily does not improve lung function it was useful in preventing patients from dropping out because of side effects when starting treatment.
Estonian: Ehkki annus 250 mikrogrammi ööpäevas kopsufunktsiooni ei paranda, aitas see ära hoida seda, et patsiendid ravi alguses tekkivate kõrvalnähtude tõttu ravi katkestavad.
English: What are the risks associated with Daxas?
Estonian: Mis riskid Daxasega kaasnevad?
English: The benefits in improving FEV1 were similar in both groups at the end of the study; however, patients who could not take 500 micrograms daily and were then just given 250 micrograms daily did not show an improvement in lung function.
Estonian: Efektiivsus FEV1 suurendamisel oli mõlemas ravirühmas sarnane, kuid patsientidel, kes ei saanud kasutada annust 500 mikrogrammi ööpäevas ja kes võtsid vaid 250 mikrogrammi ööpäevas, kopsufunktsioon ei paranenud.
English: Daxas is a medicine used to treat severe chronic obstructive pulmonary disease (COPD) in adults who have chronic bronchitis (long-term inflammation of the airways), and whose COPD flares up frequently.
Estonian: Daxas on ravim, mida kasutatakse kroonilise bronhiidina (pikaajaline hingamisteede põletik) avalduva raske kroonilise obstruktiivse kopsuhaiguse raviks täiskasvanutel, kelle haigus sageli ägeneb.
English: Daxas is not used on its own but as an ‘add-on' to treatment with bronchodilators (medicines that widen the airways in the lungs).
Estonian: Daxast kasutatakse ainult lisaks ravile bronhodilataatoritega (ravimid, mis laiendavad hingamisteid).
English: After a year, the patients who took Daxas had an average increase of 40 ml while those given placebo had an average decrease of 9 ml.
Estonian: Aasta pärast oli Daxast võtnud patsientidel FEV1 suurenenud keskmiselt 40 ml, platseebot võtnud patsientidel aga vähenenud keskmiselt 9 ml.
English: After taking 250 micrograms daily for 4 weeks, the dose is increased to 500 micrograms daily.
Estonian: Kui patsient on 4 nädalat võtnud iga päev ühe 250-mikrogrammise tableti ööpäevas, suurendatakse annust 500 mikrogrammile ööpäevas.
English: Daxas is available as tablets (250 and 500 micrograms) and can only be obtained with a prescription.
Estonian: Daxast turustatakse tablettidena (250 ja 500 mikrogrammi).
English: How is Daxas used?
Estonian: Kuidas Daxast kasutatakse?
English: These involved over 3,000 adults with severe COPD who had had at least one flare-up of their disease in the past year.
Estonian: raske kroonilise obstruktiivse kopsuhaigusega täiskasvanut, kellel oli uuringutele eelnenud aasta jooksul esinenud vähemalt üks ägenemine.
English: How does Daxas work?
Estonian: Kuidas Daxas toimib?
English: An overview of Daxas and why it is authorised in the EU
Estonian: Ülevaade ravimist Daxas ja ELis müügiloa väljastamise põhjendus
English: In addition, the patients who took Daxas had an average of 1.1 moderate or severe flare-ups of their disease, compared with 1.4 flare-ups in the patients who took placebo.
Estonian: Samuti esines mõõdukaid ja raskeid kopsuhaiguse ägenemisi Daxast võtnud patsientidel keskmiselt 1,1 korda ja platseebot võtnud patsientidel 1,4 korda.
English: Patients may need to take Daxas 500 micrograms for several weeks before it starts to have an effect.
Estonian: Ravi Daxase 500-mikrogrammiste tablettidega võib hakata mõjuma alles mitme nädala pärast.
English: What benefit of Daxas have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Daxase kasulikkus?
English: COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing air in and out of the lungs.
Estonian: Krooniline obstruktiivne kopsuhaigus on krooniline haigus, mis kahjustab või ummistab bronhe ja kopsualveoole ning raskendab sisse- ja väljahingamist.
English: Another 12-week study involving 1,323 patients examined the effect of starting treatment with Daxas 250 micrograms daily for 4 weeks before increasing the dose to 500 micrograms daily, compared with starting at the higher dose.
Estonian: Teises uuringus (12-nädalane uuring, milles osales 1323 patsienti) võrreldi kaht ravirühma: patsiendid, kes kasutasid Daxast algul annuses 250 mikrogrammi ööpäevas 4 nädala jooksul ja seejärel annuses 500 mikrogrammi ööpäevas, ja patsiendid, kes alustasid ravi kohe suurema annusega.
English: Daxas 500 micrograms was shown to be more effective than placebo (a dummy treatment) at treating COPD in two main studies.
Estonian: Kahes põhiuuringus oli annuses 500 mikrogrammi manustatud Daxas kroonilise obstruktiivse kopsuhaiguse ravis efektiivsem kui platseebo (näiv ravim).
English: The full EPAR and risk management plan summary for Vylaer Spiromax can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte ravimi Vylaer Spiromax kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Vylaer Spiromax budesonide / formoterol
Estonian: Vylaer Spiromax budesoniid/formoterool
English: The European Commission granted a marketing authorisation valid throughout the European Union for Vylaer Spiromax on 19 November 2014.
Estonian: Euroopa Komisjon andis ravimi Vylaer Spiromax müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19. novembril 2014.
English: It can be used in patients whose disease is not adequately controlled by treatment with other asthma medicines called corticosteroids and ‘short-acting beta-2 agonists' taken by inhalation, or in patients whose disease is adequately controlled by treatment with corticosteroids and ‘long-acting beta-2 agonists' taken by inhalation.
Estonian: Ravimit tohib kasutada patsientidel, kellele teised astmaravimid - inhaleeritavad kortikosteroidid ja lühitoimelised beeta-2agonistid - piisavalt ei mõju, ja patsientidel, kelle astma allub piisavalt ravile inhaleeritavate kortikosteroidide ja pikatoimeliste beeta-2-agonistidega.
English: A risk management plan has been developed to ensure that Vylaer Spiromax is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada ravimi Vylaer Spiromax võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Vylaer Spiromax?
Estonian: Mis meetmed võetakse, et tagada ravimi Vylaer Spiromax ohutu ja efektiivne kasutamine?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that Vylaer Spiromax 160/4.5 microgram and 320/9 microgram have been shown to have comparable quality and to be equivalent to the corresponding strengths of Symbicort Turbohaler.
Estonian: Inimravimite komitee järeldas, et on tõendatud ravimi Vylaer Spiromax tugevuste 160/4,5 μg ja 320/9 μg võrreldav kvaliteet ja ekvivalentsus ravimi Symbicort Turbohaleri vastavate tugevustega.
English: Vylaer Spiromax is also used to relieve the symptoms of severe chronic obstructive pulmonary disease (COPD) in adults who have had exacerbations (flare-ups) of the disease in the past despite regular treatment.
Estonian: Ravimit Vylaer Spiromax kasutatakse ka raske kroonilise obstruktiivse kopsuhaiguse sümptomite leevendamiseks täiskasvanutel, kellel on regulaarsele ravile vaatamata esinenud haiguse ägenemisi.
English: Vylaer Spiromax 160/4.5 microgram can be used for the regular treatment of asthma.
Estonian: 160/4,5 mikrogrammi tohib kasutada regulaarse astmaravimina.
English: If patients need to take more than 8 reliever inhalations per day, it is recommended they speak to their doctor to have their asthma therapy reconsidered.
Estonian: Kui ööpäevas on vaja üle 8 leevendusinhalatsiooni, on patsiendil soovitatav küsida arstilt uut astmaravi skeemi.
English: Vylaer Spiromax is a medicine that contains the active substances budesonide and formoterol.
Estonian: Vylaer Spiromax on ravim, mis sisaldab toimeainetena budesoniidi ja formoterooli.
English: For asthma reliever therapy, patients should take a separate ‘reliever inhaler' to relieve their symptoms.
Estonian: Leevendava astmaravi puhul peaksid patsiendid oma sümptomite vähendamiseks kasutama eraldi leevendusinhalaatorit.
English: The reference medicine for Vylaer Spiromax is Symbicort Turbohaler.
Estonian: Ravimi Vylaer Spiromax võrdlusravim on Symbicort Turbohaler.
English: When inhaled it mainly attaches to the receptors in the airways and causes the muscles to relax, which keeps the airways open and helps with the patient's breathing.
Estonian: Formoterooli sissehingamisel kinnitub see peamiselt hingamisteede retseptoritele ja lõõgastab lihaseid, hoides hingamisteed avatuna, nii et patsiendil on kergem hingata.
English: This means that it is similar to a ‘reference medicine' containing the same active substances, but Vylaer Spiromax is given using a different inhaler.
Estonian: See tähendab, et Vylaer Spiromax on sarnane võrdlusravimiga, mis sisaldab samu toimeaineid, kuid ravimit Vylaer Spiromax manustatakse teise inhalaatoriga.
English: This is a summary of the European public assessment report (EPAR) for Vylaer Spiromax.
Estonian: See on ravimi Vylaer Spiromax Euroopa avaliku hindamisaruande kokkuvõte.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Vylaer Spiromax, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati ravimi Vylaer Spiromax omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: What is Vylaer Spiromax and what is it used for?
Estonian: Mis on Vylaer Spiromax ja milleks seda kasutatakse?
English: For practical information about using Vylaer Spiromax, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Vylaer Spiromax kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: The two active substances in Vylaer Spiromax are well known and are present in several medicines used to treat asthma and COPD, either alone or in combination with other medicines.
Estonian: Ravimi Vylaer Spiromax mõlemat toimeainet on põhjalikult uuritud ning need sisalduvad mitmes ravimis, mida kasutatakse kas eraldi või kombinatsioonis muude ravimitega astma ja kroonilise obstruktiivse kopsuhaiguse ravis.
English: The Committee recommended that Vylaer Spiromax be given marketing authorisation.
Estonian: Komitee soovitas anda ravimi Vylaer Spiromaxi müügiloa.
English: Other information about Vylaer Spiromax
Estonian: Muu teave ravimi Vylaer Spiromax kohta
English: For more information about treatment with Vylaer Spiromax, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Vylaer Spiromax toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The benefits and risks of Vylaer Spiromax are therefore taken to be the same as those of the reference medicine.
Estonian: Seega peetakse ravimi Vylaer Spiromax kasulikkust ja riske samadeks mis võrdlusravimil.
English: Why is Vylaer Spiromax approved?
Estonian: Miks Vylaer Spiromax heaks kiideti?
English: Studies were carried out to show that Vylaer Spiromax is bioequivalent to the reference medicine (i.e. produces the same level of the active substance in the body) and that the two medicines act in the same way.
Estonian: Tehti Vylaer Spiromaxi ja võrdlusravimi bioekvivalentsuse uuringud, mis tõendasid, et Vylaer Spiromax tekitab organismis samasuguse toimeainesisalduse ja et mõlemad ravimid toimivad samamoodi.
English: Therefore, the CHMP's view was that, as for Symbicort Turbohaler, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Symbicort Turbohaleri korral, ületab ravimi Vylaer Spiromax kasulikkus sellega kaasnevad riskid.
English: It is not intended to provide practical advice on how to use Vylaer Spiromax.
Estonian: Hindamisaruandes ei anta ravimi Vylaer Spiromax kasutamise praktilisi nõuandeid.
English: How does Vylaer Spiromax work?
Estonian: Kuidas Vylaer Spiromax toimib?
English: Vylaer Spiromax is a ‘hybrid medicine'.
Estonian: Vylaer Spiromax on hübriidravim.
English: How is Vylaer Spiromax used?
Estonian: Kuidas ravimit Vylaer Spiromax kasutatakse?
English: • Stir and drink immediately
Estonian: • Segage ja jooge kohe ära
English: Date of first authorisation: 8 December 2014 Date of latest renewal: 23 September 2019
Estonian: Esmase müügiloa väljastamise kuupäev: 8. detsember 2014 Müügiloa viimase uuendamise kuupäev: 23. september 2019
English: 2132NP Hoofddorp The Netherlands
Estonian: 2132NP Hoofddorp Holland
English: Not known (frequency cannot be estimated from the available data):
Estonian: Teadmata (esinemissagedust ei saa hinnata olemasolevate andmete alusel)
English: • if your opioid medicine is to be stopped for more than 24 hours
Estonian: • tuleb teie opioidravimi kasutamine rohkem kui 24 tunniks lõpetada.
English: Moventig with drink
Estonian: Moventig koos joogiga
English: • If you miss a dose of Moventig, take it as soon as you remember.
Estonian: • Kui olete unustanud Moventigi annuse võtta, siis võtke see niipea, kui see teile meenub.
English: Patients over 65 years of age have been represented in the phase III studies.
Estonian: Vanemaid kui 65-aastaseid patsiente on kirjeldatud III faasi uuringutes.
English: Other medicines and Moventig
Estonian: Muud ravimid ja Moventig
English: Northumberland, NE61 3YA United Kingdom
Estonian: Northumberland, NE61 3YA Ühendkuningriik
English: Time to first spontaneous bowel movement
Estonian: Aeg esimese spontaanse roojamiseni
English: They were often reported as having a component of cramping discomfort.
Estonian: Sageli raporteeriti neist kui krambitaolisest ebamugavustundest.
English: What Moventig is and what it is used for
Estonian: Mis ravim on Moventig ja milleks seda kasutatakse
English: What you need to know before you take Moventig Do not take Moventig:
Estonian: Mida on vaja teada enne Moventigi võtmist Ärge võtke Moventigi:
English: Do not take Moventig if you are taking any of the following medicines (see section “Do not take Moventig”):
Estonian: Ärge võtke Moventigi, kui te kasutate mõnda järgmistest ravimitest (vt lõik “Ärge võtke Moventigi”):
English: Moventig is not recommended for use in children and adolescents below 18 years of age because it has not been studied in these age-groups.
Estonian: Moventigi ei soovitata kasutada lastel ja alla 18-aastastel noorukitel, sest seda ei ole sellel vanuserühmal uuritud.